Table 1.
Cohort characteristics and response to treatment as assessed by the SF36 PF.
| Patient | Gender (M/F) | Age (years) | Time since COVID-19 (months) | SF36 PF pre IA | SF36 PF post IA (M1) | ΔSF36 PF | Responder to IA (yes/no) |
|---|---|---|---|---|---|---|---|
| 1 | F | 36 | 39 | 15 | 70 | 55 | Yes |
| 2 | M | 41 | 25 | 25 | 70 | 45 | Yes |
| 3 | F | 56 | 15 | 25 | 65 | 40 | Yes |
| 4 | F | 37 | 21 | 45 | 85 | 40 | Yes |
| 5 | F | 52 | 23 | 45 | 80 | 35 | Yes |
| 6 | M | 59 | 31 | 35 | 65 | 30 | Yes |
| 7 | F | 51 | 38 | 15 | 35 | 20 | Yes |
| 8 | F | 31 | 19 | 40 | 60 | 20 | Yes |
| 9 | F | 59 | 32 | 20 | 35 | 15 | Yes |
| 10 | F | 50 | 31 | 15 | 30 | 15 | Yes |
| 11 | F | 36 | 10 | 15 | 25 | 10 | Yes |
| 12 | M | 36 | 9 | 40 | 50 | 10 | Yes |
| 13 | M | 46 | 32 | 20 | 30 | 10 | Yes |
| 14 | M | 57 | 14 | 50 | 60 | 10 | Yes |
| 15 | M | 33 | 23 | 25 | 30 | 5 | No |
| 16 | F | 36 | 15 | 25 | 30 | 5 | No |
| 17 | F | 44 | 14 | 5 | 5 | 0 | No |
| 18 | M | 33 | 39 | 60 | 60 | 0 | No |
| 19 | F | 37 | 15 | 30 | 25 | −5 | No |
| 20 | F | 39 | 19 | 50 | 45 | −5 | No |
F: female; IA: immunoadsorption; M: male; M1: month 1 post immunoadsorption; SF36 PF: Short Form-36 physical functioning.